PolyPid

PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PolyPid advances SHIELD II trial, secures financing for growth

PolyPid's Q2 2024 earnings call showcased progress in the SHIELD II trial and financial resilience through secured financing.
Strong leadership appointments and positive feedback on D-PLEX100's potential highlight the company's strategic strengths.
While facing timeline risks and financial challenges, PolyPid remains focused on advancing D-PLEX100 and seizing growth opportunities.
Overall, PolyPid's performance reflects a balanced approach to innovation, financial management, and commitment to achieving key milestones.

PolyPid advances SHIELD II trial with positive outlook amid financial challenges

PolyPid's Q3 2024 earnings call highlighted progress in SHIELD II trial, financial position, and challenges with increased R&D expenses. The company's focus on advancing clinical trials and managing expenses while exploring growth opportunities is key for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.

PolyPid Ltd. (NASDAQ:PYPD ) Q2 2022 Results Conference Call August 10, 2022 8:30 AM ET Company Participants Bob Yedid - IR, LifeSci Advisors Dikla Czaczkes Akselbrad - CEO Ori Warshavsky - COO, U.S. Operations Conference Call Participants Gary Nachman - BMO Capital Markets Brandon Folkes - Cantor Fitzgerald Michael Parolari - Raymond James Roy Buchanan - JMP Securities Operator Greetings, and welcome to the PolyPid Second Quarter 2022 Conference Call.

PolyPid Ltd. (PYPD) CEO Dikla Czaczkes Akselbrad on Q2 2022 Results - Earnings Call Transcript

PETACH TIKVA, Israel, Aug. 10, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and six months ended June 30, 2022.

PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results

PolyPid to potentially receive over $110 million in upfront and milestone payments as well as royalties on net sales

PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe

PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 10, 2022. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide an update on business operations.

PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022

Efficacy Data of D-PLEX 100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting

Company Previously Announced Planned CEO Transition Following Retirement of Amir Weisberg Company Previously Announced Planned CEO Transition Following Retirement of Amir Weisberg

PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO

PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a key opinion leader (“KOL”) webinar on the cost of managing surgical site infections (“SSIs”) on Thursday, June 23, 2022, at 10:00 AM Eastern Time.

PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections

Phase 2 clinical data on the efficacy of D-PLEX 100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation

PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022

PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life Sciences Conference, which is being held in New York City, on June 15-16, 2022.

PolyPid to Present at the JMP Securities 2022 Life Sciences Conference

PETACH TIKVA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that animal studies related to OncoPLEX, the Company's lead intra-tumoral product candidate in oncology applied as a paste to the resection bed during surgery, have been published in an abstract in the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Abstract Book. The abstract, reduction in local tumor recurrence in a murine R2 resection model comparing locally administered docetaxel-releasing product, OncoPLEX, versus systemic docetaxel, demonstrated that locally administered OncoPLEX potentially decreases the likelihood of tumor recurrence, with reduced side effects, compared to systemically administered chemotherapy agents.

PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects

PETACH TIKVA, Israel, May 31, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the completion of enrollment in the SHIELD I Phase 3 study of D-PLEX100 for the prevention of surgical site infections (SSIs) in abdominal surgery. Following a review of unblinded efficacy data from the first 750 enrolled patients in the trial, the independent Data Safety Monitoring Board (DSMB) recently recommended concluding the study upon enrollment of 950 patients, which is the minimum number of targeted patients in the trial protocol.

PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery

The independent Data Safety Monitoring Board (DSMB) has recommended concluding enrollment in PolyPid Ltd's (NASDAQ: PYPD) SHIELD I Phase 3 study of D-PLEX100 to prevent surgical site infections (SSIs) abdominal tissue surgery. DSMB recommended stopping enrollment upon 950.

Why PolyPid Shares Are Gaining Today

• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days

PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

The mean of analysts' price targets for PolyPid Ltd. (PYPD) points to a 288.7% upside in the stock.

Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 289%: Read This Before Placing a Bet

PolyPid Ltd. (NASDAQ:PYPD ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors Amir Weisberg - Chief Executive Officer Dikla Czaczkes Akselbrad - Executive Vice President and Chief Financial Officer Ori Warshavsky - Chief Operating Officer, US Operations Conference Call Participants Balaji Prasad - Barclays Michael Parolari - Raymond James Gary Nachman - BMO Capital Markets Brandon Folkes - Cantor Fitzgerald Roy Buchanan - JMP Securities Operator Greetings and welcome to the PolyPid First Quarter 2022 Conference Call.

PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q1 2022 Results - Earnings Call Transcript

•  Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX 100   in Abdominal   Soft Tissue   Surgery Expected to Occur Imminently

PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results

PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022

Presentation evaluates the effect of D-PLEX 100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients

PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine

PolyPid develops a platform technology to provide locally controlled and continuous delivery of medications. Lead product candidate D-PLEX100 is investigated for the prevention of sternal and abdominal surgical site infections serving a huge market.

PolyPid: Strong Pipeline, Close Catalysts

Presentation evaluates the addition of D-PLEX₁₀₀ to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgery Presentation evaluates the addition of D-PLEX₁₀₀ to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgery

PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting

Secured Loan facility with Kreos Capital Extends Company's Cash Runway into the Second Quarter of 2023 Secured Loan facility with Kreos Capital Extends Company's Cash Runway into the Second Quarter of 2023

PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility

Presentation Evaluates Efficacy of D-PLEX 100 in Reducing Surgical Site Infection Rates in Elective Colorectal Surgery

PolyPid to Deliver Poster Presentation at SAGES 2022

Unblinded Interim Analysis Expected in the Second Quarter of 2022 Unblinded Interim Analysis Expected in the Second Quarter of 2022

PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q4 2021 Results - Earnings Call Transcript

• FDA A greed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Co mplete their 30 - day F ollow-up • Recruitment Progressing as Planned with Approximately 6 80 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100  in Abdominal Soft Tissue S urgery . Expect to R each 750 E nrolled P atients by E nd of F irst Q uarter 2022 and H ave Unblinded Interim Analysis D uring the S econd Q uarter of 2022 • Recently Completed Planned 500 - P atient Blinded Sample Size Re a ssessment of SHIELD I Support s the C ontinuation of the T rial • Conference Call S cheduled for Today at 8:30 AM ET

News for PolyPid Stock (PYPD)